Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardunizumab plus chemotherapy for first-line PD-L1-negative advanced or metastatic NSCLC
ChiCTR2300076501Phase 2Not yet recruiting
- Sponsor
- Anhui Chest Hospital
- Start
- Oct 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in non-small cell lung cancer (NSCLC), sponsored by Anhui Chest Hospital. Primary endpoint: overall response rate. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300076501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076501.